MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$3.10 USD
-0.16 (-4.91%)
Updated Apr 25, 2024 03:56 PM ET
After-Market: $3.23 +0.13 (4.19%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MEIP 3.10 -0.16(-4.91%)
Will MEIP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MEIP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MEIP
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer
MEIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails
Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises
Other News for MEIP
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (AvastinĀ®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma prioritizes voruciclib, will not continue with 2nd ROC
MEI Pharma reports data from study evaluating ME-344/Avastin combo for mCRC
MEI Pharma shelves plans for a second return of capital